David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Neuroethics 2 (2):75-87 (2009)
The hopes and fears expressed in the debate on human enhancement are not always based on a realistic assessment of the expected possibilities. Discussions about extreme scenarios may at times obscure the ethical and policy issues that are relevant today. This paper aims to contribute to an adequate and ethically sound societal response to actual current developments. After a brief outline of the ethical debate concerning neuro-enhancement, it describes the current state of the art in psychopharmacological science and current uses of psychopharmacological enhancement, as well as the prospects for the near future. It then identifies ethical issues regarding psychopharmacological enhancements that require attention from policymakers, both on the professional and on the governmental level. These concern enhancement research, the gradual expansion of medical categories, off-label prescription and responsibility of doctors, and accessibility of enhancers on the Internet. It is concluded that further discussion on the advantages and drawbacks of enhancers on a collective social level is still needed.
|Keywords||Psychopharmacology Enhancement Policy|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
J. M. Appel (2008). When the Boss Turns Pusher: A Proposal for Employee Protections in the Age of Cosmetic Neurology. Journal of Medical Ethics 34 (8):616-618.
Nick Bostrom (2003). Human Genetic Enhancements: A Transhumanist Perspective. [REVIEW] Journal of Value Inquiry 37 (4):493-506.
Allen E. Buchanan, Dan W. Brock, Norman Daniels & Daniel Wikler (2000). From Chance to Choice. Cambridge University Press.
Kathy Davis (2007). Rethinking "Normal". Hastings Center Report 37 (3):44-47.
Citations of this work BETA
Nicholas S. Fitz, Roland Nadler, Praveena Manogaran, Eugene W. J. Chong & Peter B. Reiner (2014). Public Attitudes Toward Cognitive Enhancement. Neuroethics 7 (2):173-188.
Toni Pustovrh & Franc Mali (2014). Exploring Some Challenges of the Pharmaceutical Cognitive Enhancement Discourse: Users and Policy Recommendations. Neuroethics 7 (2):137-158.
Similar books and articles
Allen Buchanan (2008). Enhancement and the Ethics of Development. Kennedy Institute of Ethics Journal 18 (1):pp. 1-34.
Alex Rajczi (2008). One Danger of Biomedical Enhancements. Bioethics 22 (6):328–336.
Matthis Synofzik (2009). Ethically Justified, Clinically Applicable Criteria for Physician Decision-Making in Psychopharmacological Enhancement. Neuroethics 2 (2):89-102.
Jonathan Wolff (2009). Disability, Status Enhancement, Personal Enhancement and Resource Allocation. Economics and Philosophy 25 (1):49-68.
Thomas Douglas (2008). Moral Enhancement. Journal of Applied Philosophy 25 (3):228-245.
Jakov Gather (2011). The Evaluation of Psychopharmacological Enhancers Beyond a Normative “Natural”–“Artificial” Dichotomy. Medicine Studies 3 (1):19-27.
Nicole Hassoun (2008). Nanotechnology, Enhancement, and Human Nature. NanoEthics 2 (3):289-304.
Katherine Drabiak-Syed (2011). Reining In the Pharmacological Enhancement Train: We Should Remain Vigilant About Regulatory Standards for Prescribing Controlled Substances. Journal of Law, Medicine and Ethics 39 (2):272-279.
L. L. E. Bolt (2007). True to Oneself? Broad and Narrow Ideas on Authenticity in the Enhancement Debate. Theoretical Medicine and Bioethics 28 (4):285-300.
Added to index2009-02-14
Total downloads39 ( #46,476 of 1,099,750 )
Recent downloads (6 months)5 ( #66,740 of 1,099,750 )
How can I increase my downloads?